Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Guoquan Zhang
University of Missouri Columbia, Department: Veterinary Sciences
Should you be removed from our database? Contact us at [email protected]. Read more below.
ZenVax, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
As described in Dr. Guoquan Zhang and Dr Yan Zhang’s disclosure, ZenVax, LLC will
collaborate with the University of Missouri to apply for grants and contracts from NIH,
DOD, CDC and USDA. The company is planning to contract with the University of
Missouri to conduct vaccine development research at the University facilities.
This project aim is to develop a safe and effective vaccine against Q fever. To achieve
this goal, this application aims to define the first multivalent vaccine for Q fever
targeting both C burnetii phase I lipopolysaccharide and protein.
It is the determination of the University of Missouri’s Conflict of Interest Committee that
Dr. Guoquan Zhang and Dr Yan Zhang’s equity interest, research support, and research
with the entity could directly affect the design, conduct and reporting of the research
Mimetic Peptides-Mediated Protection Against Coxiella burnetii Infection
Project Narrative: Development of a safe and effective vaccine for prevention of human Q fever remains an important goal for public health and national biosecurity. To achieve this goal, this application aims to define the first multivalent vaccine for Q fever targeting both C. burnetii phase I lipopolysaccharide and protein.
Filed on August 21, 2018.
Tell us what you know about Guoquan Zhang's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Guoquan Zhang filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Guoquan Zhang | University of Missouri Columbia | Conflict of Interest | ZenVax, LLC | Value cannot be readily determined |
| Guoquan Zhang | University of Missouri Columbia | Conflict of Interest | ZenVax, LLC | Value cannot be readily determined |
| Guoquan Zhang | University of Missouri Columbia | Conflict of Interest | ZenVax, LLC | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.